Intervention | Base case comparator | Additional comparators tested in scenario analyses | |||
---|---|---|---|---|---|
Pembrolizumab | DTIC | Ipilimumab | Temozolomide | Paclitaxel/carboplatin | |
Survival extrapolation for progression free survival (PFS) and overall survival (OS) | |||||
PFS funtional forma | Weibull | Constant HR from NWMA | Log-normal | Assumed the same as for DTIC | Assumed the same as for DTIC |
OS functional formb | Lognormal model for HR | Constant HR from NWMA followed by registry data | KEYNOTE-006 ipilimumab arm, long-term ipilimumab data from Schadendorf et al. [4] and AJCC data. | Assumed the same as for DTIC | Assumed the same as for DTIC |
Utility: mean (95% confidence interval) | |||||
Utility: ≥ 360 days till death | 0.82 (0.81, 0.83) | ||||
Utility [270,360) days till death | 0.74 (0.69, 0.79) | ||||
Utility [90, 270) days till death | 0.69 (0.65, 0.73) | ||||
Utility [30,90) days till death | 0.60 (0.54, 0.66) | ||||
Utility < 30 days till death | 0.42 (0.29, 0.56) | ||||
Utility for PFS | 0.82 (0.81, 0.83) | 0.79 (0.77, 0.80) | 0.82 (0.81, 0.83) | ||
Utility for post-progression | 0.72 (0.70, 0.74) | ||||
Adverse events (AE) | |||||
Colitis, grade 3 and abovef | 1.8% | 0.0% | 6.3% | 0.0% | 0.0% |
Diarrhea (excl. colitis), grade 2 and above | 3.6% | 0.0% | 7.8% | 0.0% | 0.0% |
Endocrine disorders, any grade | 12.3% | 0.0% | 5.5% | 3.0% | 0.0% |
Neutropenia, grade 3 and above | 0.0% | 11.9% | 0.0% | 3.0% | 18.8% |
Thrombocytopenia | 0.0% | 5.1% | 0.0% | 7.0% | |
Hemorrhage (non-CNS/pulmonary) | 0.0% | 0.0% | 0.0% | 5.8% | |
Asthenia | 0.0% | 0.0% | 0.0% | 3.0% | 0.0% |
Headache | 0.0% | 0.0% | 0.0% | 6.0% | 0.0% |
Pain | 0.0% | 0.0% | 0.0% | 7.0% | 0.0% |
Constipation | 0.0% | 0.0% | 0.0% | 3.0% | 0.0% |
Nausea | 0.0% | 0.0% | 0.0% | 4.0% | 0.0% |
Vomiting | 0.0% | 0.0% | 0.0% | 5.0% | 0.0% |
# of treatment for endocrine disorders | 3.23 | 0 | 3.00 | 0 | 0 |
Costs of AE management | $863 | $92 | $1196 | $672 | $767 |
Disutility of an AEe | 0.15 over 8 weeks | ||||
Drug costs | |||||
Unit cost of drug | $2564 per 100 mg vial | $56 per 100 mg vial | $ 5.897 per 50 mg vial | $14.28 per 20 mg vial | Paclitaxel: $25.77 per 100 mg Carboplatin: $30.69 per 450 mg |
Dose per administration | 200 mg Q3W | 1000 mg/m2 | 3 mg/kg Q3W for a maximum of 4 doses | 1000 mg/m2 | Paclitaxel: 300 mg Carboplatin: 525 mg |
Mean number of vials per 3 weeks (based on whole vials at the patient level) | 1.84 vials | 17.5 | 4,40 of 50 mg vials | 1750 mg (1000 mg/m2) | Paclitaxel: 3 of 100 mg vials Carboplatin: 1.17 of 450 mg vials |
Mean cost of drug administrationc | $91.67 per administration | $91.67 per administration | $91.67 per administration | $0 (oral drug) | $91.67 per administration |
Total drug cost for each dose | $4706 | $980 | $25.937 | $1.249,50 | Paclitaxel: $77.31 Carboplatin: $61.38 Total: $138.69 |
Disease management costsd | |||||
Management during PFS | $144/week | ||||
Management during post progression | $109/week | ||||
Death related costs | $24,089 (last 6 months of life) |